Organization | Health Resources and Services Administration (HRSA)

Health Resources and Services Administration (HRSA) Report issue

Government Phase 2 Phase 3 Phase 4

Founded: Bethesda MD United States (1982)

Organization Overview

First Clinical Trial

2000

NCT00315588

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Health Resources and Services Administration | Health Resources and Services Administration (HRSA)

Active Ingredients

Drugs in Phase 4 Trials (3)

amino acids (Freamine) (1 trial)

buprenorphine (1 trial)

icosapent ethyl (vascepa) (1 trial)

Drugs in Phase 3 Trials (2)

antihemophilic factor viii (Recombinant), Fc-fusion protein (Eloctate) (2 trials)

emicizumab (Hemlibra) (2 trials)

Drugs in Phase 2 Trials (3)

allogeneic pancreatic islet cells (2 trials)

ferrous sulfate (1 trial)

sertraline (zoloft) (1 trial)

Drugs in Other Trials (3)

alteplase (Activase) (1 trial)

clofazimine (lamprene) (1 trial)

xylitol (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Autism Spectrum Disorder (Phase 2)

Autistic Disorder (Phase 2)

Child Development Disorders, Pervasive (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Disease (Phase 2)

Hemophilia A (Phase 3)

Opioid-Related Disorders (Phase 4)

Parasomnias (Phase 2)

Premature Birth (Phase 4)

Sleep Initiation and Maintenance Disorders (Phase 2)

Sleep Wake Disorders (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 11
# of Trial APIs: 11